Skip to Content

Generic Revatio Availability

Revatio is a brand name of sildenafil, approved by the FDA in the following formulation(s):

REVATIO (sildenafil citrate - for suspension;oral)

  • Manufacturer: PFIZER
    Approval date: August 30, 2012
    Strength(s): EQ 10MG BASE/ML [RLD]

REVATIO (sildenafil citrate - solution;intravenous)

  • Manufacturer: PFIZER
    Approval date: November 18, 2009
    Strength(s): EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML) [RLD] [AP]

REVATIO (sildenafil citrate - tablet;oral)

  • Manufacturer: PFIZER
    Approval date: June 3, 2005
    Strength(s): EQ 20MG BASE [RLD] [AB]

Has a generic version of Revatio been approved?

A generic version of Revatio has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Revatio and have been approved by the FDA:

sildenafil citrate solution;intravenous

  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: April 1, 2015
    Strength(s): EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML) [AP]

sildenafil citrate tablet;oral

  • Manufacturer: ACTAVIS GRP PTC
    Approval date: February 25, 2013
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: AMNEAL PHARMS
    Approval date: February 28, 2013
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: APOTEX CORP
    Approval date: November 6, 2012
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: DR REDDYS LABS LTD
    Approval date: November 6, 2012
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: HETERO LABS LTD V
    Approval date: November 26, 2014
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: MACLEODS PHARMS LTD
    Approval date: December 17, 2013
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: November 9, 2012
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: TEVA PHARMS
    Approval date: January 7, 2013
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: TORRENT PHARMS LTD
    Approval date: November 6, 2012
    Strength(s): EQ 20MG BASE [AB]
  • Manufacturer: WATSON LABS INC
    Approval date: November 6, 2012
    Strength(s): EQ 20MG BASE [AB]

Note: No generic formulation of the following product is available.

  • sildenafil citrate - for suspension;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Revatio. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • August 30, 2015 - REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
    • August 30, 2015 -
    • March 1, 2016 -
    • January 31, 2017 - NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
    • January 31, 2017 - INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Hide